Achromatopsia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Achromatopsia Market Outlook

Thelansis’s “Achromatopsia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Achromatopsia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Achromatopsia Overview

Achromatopsia is a rare autosomal recessive retinal disorder that leads to color blindness, nystagmus, photophobia, and severely reduced visual acuity due to cone function impairment or absence. It is characterized by reduced visual acuity, pendular nystagmus, photophobia, a small central scotoma, and reduced or complete loss of color discrimination. Most individuals with ACHM exhibit complete ACHM, where all three types of cones lack function, resulting in severe symptoms. In some rare cases, incomplete ACHM occurs, with milder symptoms due to the presence of functional cones. ACHM is associated with five genes: GNAT2, PDE6C, PDE6H, CNGA3, and CNGB3, all critical components of the cone phototransduction cascade. CNGB3 mutations are the most common, followed by CNGA3, while others are rare causes of ACHM. Achromatopsia comes in two types: complete, with no functional cones, and incomplete, with some functional cones. The differential diagnosis includes conditions like blue cone monochromatism, Leber congenital amaurosis, other cone dystrophies, and cerebral achromatopsia.

• Unfortunately, there is currently no cure for achromatopsia, affecting about one in 30,000 live births.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: